Shao Yangzhen, Redfors Bjorn, Benoist David, Gizurarson Sigfus, Omerovic Elmir
Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Bruna stråket 16, 413 45, Gothenburg, Sweden,
Mol Cell Biochem. 2014 Aug;393(1-2):191-7. doi: 10.1007/s11010-014-2060-0. Epub 2014 Apr 27.
Arrhythmias have been treated for a long time with drugs that mainly target the ionic pumps and channels. These anti-arrhythmic regimens per se introduce new arrhythmias, which can be detrimental to patients. Advances in development of novel pharmacology without introduction of iatrogenic arrhythmias are thus favorable for an effective treatment of arrhythmias. Electrophysiological stability of the heart has been shown to be closely associated with cardiac metabolism. The present effective anti-arrhythmic drugs such as beta-blockers and amiodarone have profound beneficial effects in regulating myocardial metabolism. Aiming at decreasing production of toxic metabolites or preventing accumulation of arrhythmogenic lipids perhaps is a good strategy to effectively control arrhythmias. Therefore, a better understanding of the pro-arrhythmic profiles of cardiac metabolites helps to explore a new generation of metabolically oriented anti-arrhythmic medications. In this review, we present several lipid metabolites and summarize their arrhythmogenic characteristics.
心律失常长期以来一直使用主要针对离子泵和通道的药物进行治疗。这些抗心律失常方案本身会引发新的心律失常，对患者可能有害。因此，开发不会引发医源性心律失常的新型药理学进展有利于心律失常的有效治疗。心脏的电生理稳定性已被证明与心脏代谢密切相关。目前有效的抗心律失常药物，如β受体阻滞剂和胺碘酮，在调节心肌代谢方面具有深远的有益作用。旨在减少有毒代谢物的产生或防止致心律失常脂质的积累，可能是有效控制心律失常的一个好策略。因此，更好地了解心脏代谢物的促心律失常特征有助于探索新一代以代谢为导向的抗心律失常药物。在这篇综述中，我们介绍了几种脂质代谢物并总结了它们的致心律失常特征。
